Unsupported Browser
The American College of Surgeons website is not compatible with Internet Explorer 11, IE 11. For the best experience please update your browser.
Menu
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
ACS
ACS Case Reviews

Diagnostic Challenges of Periampullary Adenocarcinoma in a Post-Ivor Lewis Esophagectomy Patient

December 19, 2024

Abstract

Background

With improved survival after esophageal cancer treatment, the incidence of second primary malignancies (SPMs) is expected to rise. Patients who have undergone esophagectomy and later require pancreatoduodenectomy pose unique challenges. Gastroduodenal artery (GDA) ligation, often necessary during pancreatoduodenectomy, can compromise the vascular supply of a gastric conduit. Previous reports describe various approaches: GDA preservation, ligation with reliance on collateral circulation, ligation with revascularization, or complete sacrifice of the gastric conduit with colonic interposition for reconstruction.

Summary

A patient with a history of Ivor Lewis esophagectomy for esophageal adenocarcinoma presented with jaundice and was diagnosed with ampullary adenocarcinoma. Axial imaging and angiography revealed the gastric conduit’s sole vascular supply was the right gastroepiploic artery. While we were prepared for microvascular revascularization or colonic interposition if needed, we successfully performed a GDA-preserving pancreatoduodenectomy. Additionally, we performed a Roux-en-Y gastrojejunostomy instead of the standard loop to minimize conduit manipulation and ensure tension-free anastomosis. The patient recovered well and was eligible for adjuvant chemotherapy but declined this option.

Conclusion

Surgical management of SPMs in patients may be limited by prior therapies. In these situations, it is best for surgeons to consider conservative operative strategies for improved outcomes and timely additionally indicated treatments.

Key Words

pancreatoduodenectomy; esophagectomy

Abbreviations

gastroduodenal artery (GDA)
carbohydrate antigen 19-9 (CA 19-9)
esophagogastroduodenoscopy (EGD)
endoscopic ultrasound (EUS)
superior mesenteric artery (SMA)
superior mesenteric vein (SMV)
right gastric artery (RGA)
pancreatic ductal adenocarcinoma (PDAC)
cholangiocarcinoma (CCA)
pancreatoduodenectomy (PD)
length of stay (LOS)
overall survival (OS)
recurrence-free survival (RFS)
renal cell carcinoma (RCC)
squamous cell carcinoma (SCC)
intraductal papillary mucinous neoplasm (IPMN)


Case Description

Standard pancreatoduodenectomy for periampullary malignancies involves division of the gastroduodenal artery (GDA). However, this approach poses challenges when a patient has undergone a prior esophagectomy with a gastric conduit dependent on the right gastroepiploic artery (a terminal branch of the GDA), requiring alternative surgical strategies. Here, we present a patient with a history of Ivor Lewis esophagectomy who subsequently developed resectable ampullary adenocarcinoma.

A 58-year-old male presented with jaundice, dark urine, and pruritis. Labs revealed elevated bilirubin, liver enzymes, and carbohydrate antigen 19-9 (CA 19-9). CT scan demonstrated intra- and extrahepatic biliary and pancreatic ductal dilation without identifiable masses or strictures. Esophagogastroduodenoscopy (EGD) revealed an ampullary mass, and endoscopic ultrasound (EUS) confirmed a 2 cm malignant-appearing mass without lymphadenopathy. Biopsy confirmed invasive adenocarcinoma (T1cN0).

Three years prior, the patient was diagnosed with esophageal adenocarcinoma (cT3N0). Treatment included neoadjuvant chemotherapy followed by a standard open Ivor Lewis esophagectomy. During this surgery, the left gastric and short gastric arteries were divided, and a conduit was fashioned from the greater curvature of the stomach, leaving the right gastroepiploic artery as the primary blood supply to the gastric conduit (Figure 1). Notably, pathology demonstrated a complete response to neoadjuvant therapy. The patient recovered well, requiring only occasional endoscopic dilations for dysphagia. At the time of presentation, he was two years post-esophagectomy with no evidence of recurrence.

Figure 1. Schematic Illustration of Gastric Conduit Arterial Supply Post-Ivor Lewis Esophagectomy.

Following a clinic discussion, the patient opted for surgical resection of the ampullary lesion. Preoperative angiography (Figure 2) delineated the gastric conduit’s vasculature, confirming exclusive reliance on the right gastroepiploic artery and demonstrating no contributions from the SMA or short gastric arteries, as suggested by prior axial imaging (Figure 3). The patient completed a bowel prep the evening before surgery, allowing for the possibility of colonic interposition.

Figure 2. Preoperative Diagnostic Angiogram of Gastric Conduit. Published with Permission

Right gastroepiploic artery is the primary supply to the conduit following prior esophagectomy. Left gastric and short gastric arteries have been ligated. Right gastric artery, though likely patent, is diminutive
Right gastroepiploic artery is the primary supply to the conduit following prior esophagectomy. Left gastric and short gastric arteries have been ligated. Right gastric artery, though likely patent, is diminutive

Figure 3. Preoperative CT Scan (axial view). Published with Permission

Gastric conduit vascularized by the right gastroepiploic artery
Gastric conduit vascularized by the right gastroepiploic artery

During the pancreatoduodenectomy, the gastric conduit was exposed, and the right gastroepiploic vessels were carefully isolated and protected. The gastroepiploic vein was traced to its superior mesenteric vein (SMV) insertion. The GDA was located in the porta hepatis, and dissection was carried distally, ligating superior pancreaticoduodenal branches. To address previous emptying issues and the tumor’s ampullary location, the decision was made to resect the duodenum, favoring this over a pylorus-preserving approach.

The GDA dissection was continued, revealing its bifurcation into the right gastroepiploic artery supplying the conduit. Intraoperative ultrasonography was repeatedly used to confirm anatomy and adequate blood flow to the conduit. Despite slight vasospasm, the pulse remained palpable, and the conduit was well-perfused. The gastroepiploic vessels were gently retracted leftward using a Penrose drain to protect the pedicle while tunneling between the pancreas and portal vein (Figure 4).

Figure 4. Intraoperative View of Intact Gastroepiploic Pedicle. Published with Permission

A Blumgart pancreaticojejunostomy was performed, positioning the gastroepiploic vessels posterior to the anastomosis. The cephalad position of the gastric conduit and significant adhesions limited mobilization, necessitating a Roux-en-Y gastrojejunostomy instead of the standard loop procedure.

Pathological examination revealed a moderately differentiated pancreatic adenocarcinoma originating in the uncinate process with direct ampullary invasion. Focally positive margins were noted on the uncinate, vascular groove, and posterior surface, along with involvement of six of fourteen lymph nodes (pT2N2).

The patient’s postoperative recovery was uneventful, and he was discharged on the fifth day. Following consultation with his local medical oncologist, he was deemed eligible for adjuvant multi-agent chemotherapy. However, the patient declined further treatment due to lingering side effects from previous chemotherapy regimens.

Discussion

The rising incidence of esophageal adenocarcinoma and improved survival rates suggest clinicians are increasingly likely to manage patients who develop second primary malignancies after esophagectomy.2 In these cases, treatment approaches for resectable second primaries may face constraints due to the patient’s prior surgical history.

In fit patients with resectable disease, esophagectomy is often the preferred local therapy for esophageal adenocarcinoma.3 The most common procedures include transhiatal,4 Ivor Lewis,5 and McKeown esophagectomy.6 Alimentary continuity is typically restored by using the stomach as a neo-esophagus or creating a gastric conduit. This conduit relies primarily upon the right gastroepiploic artery (RGEA)—a terminal branch of the GDA—with minor contributions from the right gastric artery (RGA).7 As the GDA is routinely ligated during pancreatoduodenectomy, post-esophagectomy patients requiring pancreatic resection present a unique challenge.

Literature on pancreatoduodenectomy modifications for patients with prior esophagectomy is limited, though some technical adaptations exist to preserve the GDA and RGA.8 Our preferred approach, based on existing publications (Table 1), was GDA-sparing pancreatoduodenectomy.9‒17

Authors
Clinical History
Surgical Approach
Outcome

Ikeda et al.
(Arch Surg 2006)9

Patient with previous esophagectomy with gastric conduit
Presented with pancreatic cancer (PDAC)

GDA-preserving pancreatoduodenectomy (PD)
Length of stay (LOS) = 31 days; received adjuvant gemcitabine

Patient with previous subtotal gastrectomy
Presented with cholangiocarcinoma (CCA)

GDA-preserving PD with Roux-en-Y duodenojejunostomy
Overall survival (OS) = 3 years

Orii et al.
(Int J Surg Case Rep 2019)10

Previous esophagectomy with gastric conduit
Presented with PDAC

GDA-preserving PD with Roux-en-Y gastrojejunostomy

LOS = 36 days
Recurrence-free survival (RFS) = 63 months

Okimoto et al.
(Int J Surg Case Rep 2014)11

Previous esophagectomy with gastric conduit
Presented with cholangiocarcinoma (CCA)

GDA-preserving PD
LOS = 46 days

Addeo et al.
(Langenbecks Arch Surg)12

Previous esophagectomy with gastric conduit
Presented with renal cell carcinoma (RCC) metastasis

GDA-preserving PD
LOS = 30 days

Fragulidis et al.
(J Gastrointest Surg 2011)13

Previous transhiatal esophagectomy with gastric conduit
Presented with PDAC

GDA-preserving PD

LOS = 15 days
Received adjuvant gemcitabine
RFS = 8 months (liver)
OS = 14 months

Kurosaki et al.
(Surg Today 2000)14

Synchronous esophageal squamous cell carcinoma (SCC) and intraductal papillary mucinous neoplasm (IPMN)

One-stage transhiatal esophagectomy and GDA-preserving PD

LOS = 43 days
RFS = 7 weeks (esophageal anastomosis) s/p radiation therapy
OS = 5 years

Uehara et al.
(Surg Today 2004)15

Previous esophagectomy with gastric conduit
Presented with IPMN

GDA-preserving PD
N/A

Hirashita et al.
(Surg Case Rep 2019)16

Two patients, each with previous subtotal gastrectomy
Presented with CCA

GDA-preserving PD
LOS = 18 and 29 days, respectively

Inoue et al.
(Surg Today 2014)18

Previous esophagectomy with gastric conduit
Presented with PDAC

PD with microvascular reconstruction (GDA)

LOS = 56 days
RFS = 6 months

Okochi et al.
(Int J Surg Case Rep 2015)19

Previous esophagectomy with gastric conduit
Presented with PDAC

PD with microvascular reconstruction (middle colic)
LOS = 2 months

Minagawa et al.
(Surg Case Rep 2020)20

Previous esophagectomy with gastric conduit
Presented with PDAC

PD with microvascular reconstruction (middle colic)

LOS = 90 days
Gastrojejunostomy leak managed conservatively
Received adjuvant S-1
RFS = 15 months

De Garcia de la Vega et al.
(Acta Chir Belg 2021)21

Synchronous esophageal and ampullary adenocarcinoma
One-stage esophagectomy, total gastrectomy, colonic interposition, and PD

Received adjuvant therapy
Hepatic recurrence
OS = 2 years

Belyaev et al.
(Langenbecks Arch Surg 2009)22

History of severe chronic pancreatitis
Presented with esophageal adenocarcinoma

One-stage esophagectomy, total gastrectomy, colonic interposition, and PD

LOS = 28 days
RFS = 30 months

Jayaprakash et al.
(Patient Saf Surg 2009)23

Synchronous esophagogastric junction and ampullary adenocarcinoma
One-stage esophagectomy, total gastrectomy, Roux-en-Y esophagojejunostomy, and PD

LOS = 22 days
RFS = 6 months

Honig et al.
(J Pancreat Cancer 2020)24

Previous McKeown esophagectomy with gastric conduit
Presented with PDAC

PD with technically difficult duodenojejunostomy

LOS = 6 days
DJ leak managed endoscopically

Should GDA preservation prove impossible, our alternative plans were:

  • Revascularization: Anastomosing the RGEA to the remnant GDA18 or the middle colic artery.19,20
  • Conduit Sacrifice: If preserving the gastric conduit was impossible, we planned gastrectomy with alimentary continuity re-established via colonic interposition21,22 or esophagojejunostomy.23

A single report describes a standard pancreatoduodenectomy with GDA ligation, relying on the RGA to supply the gastric conduit.24 However, this was not feasible for our patient due to minimal RGA flow on angiography.

The decision to utilize a Roux limb for the gastrojejunostomy adds a unique element to this case. While most published reports describe a standard loop technique, only two prior cases document the Roux limb approach.9,10 Given the anatomic location of the gastric conduit and associated adhesions, adequate mobilization for a loop gastrojejunostomy would have increased risk and potentially placed the anastomosis under excessive tension. A previous report where a standard loop technique was performed near the hiatus resulted in an anastomotic leak necessitating multiple reinterventions.24 Mindful of this risk, and anticipating likely adjuvant therapy,25 we prioritized minimizing potential complications for our patient. Notably, unlike many published case reports that detail postoperative issues or lengthy hospital stays, this patient fortunately avoided both.

Conclusion

This case demonstrates successful pancreatoduodenectomy after prior Ivor Lewis esophagectomy. Preservation of the gastroduodenal and right gastroepiploic arteries, along with a Roux-en-Y gastrojejunostomy, highlights the importance of surgical strategies that minimize morbidity in complex cases, facilitating timely adjuvant therapy.

Lessons Learned

As the incidence of secondary malignancies after esophageal cancer treatment increases, surgeons will likely encounter more cases where surgical approaches are influenced by prior therapies. Conservative operative strategies may improve patient outcomes and potentially expedite adjuvant therapy in complex scenarios. However, surgeons should always be prepared by developing contingency plans when operating on patients with complex surgical and oncologic histories.

Authors

Robbins KJa; Gauthier JMb; Kozower BDb; Fields RCa

Author Affiliations

  1. Department of Surgery, Section of Surgical Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110
  2. Department of Surgery, Division of Cardiothoracic Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO 63110

Corresponding Author

Keenan J. Robbins, MBBS, MPHS
Department of Surgery
660 S. Euclid Avenue
Wohl Building, 9th Floor
St. Louis, MO 63110
Email: kjrobbins@wustl.edu

Disclosure Statement

The authors have no conflicts of interest to disclose.

Funding/Support

Research reported in this publication was supported by the Washington University School of Medicine Surgical Oncology Basic Science and Translational Research Training program grant T32CA009621, from the National Cancer Institute (NCI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Received: July 4, 2022
Revision received: October 27, 2022
Accepted: January 30, 2023

References

  1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER*Explorer: an interactive website for SEER cancer statistics. Accessed May 17, 2022. https://seer.cancer.gov/explorer/
  2. Das A, Thomas S, Zablotska LB, Neugut AI, Chak A. Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol. 2006;40(5):405-411. doi:10.1097/00004836-200605000-00008
  3. Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(7):855-883. doi:10.6004/jnccn.2019.0033
  4. Orringer MB, Marshall B, Chang AC, Lee J, Pickens A, Lau CL. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246(3):363-374. doi:10.1097/SLA.0b013e31814697f2
  5. Lewis I. Carcinoma of the oesophagus. Radical Resection with oesophago-gastrostomy for a Midthoracic Growth by a Right Transpleural Approach. Proc R Soc Med. 1945;38(9):483-484.
  6. D’Amico TA. Mckeown esophagogastrectomy. J Thorac Dis. 2014;6 Suppl 3(Suppl 3):S322-S324. doi:10.3978/j.issn.2072-1439.2014.03.28
  7. Liebermann-Meffert DM, Meier R, Siewert JR. Vascular anatomy of the gastric tube used for esophageal reconstruction. Ann Thorac Surg. 1992;54(6):1110-1115. doi:10.1016/0003-4975(92)90077-h
  8. Gauvin JM, Sarmiento JM, Sarr MG. Pylorus-preserving pancreaticoduodenectomy with complete preservation of the pyloroduodenal blood supply and innervation. Arch Surg. 2003;138(11):1261-1263. doi:10.1001/archsurg.138.11.1261
  9. Ikeda M, Hasegawa K, Akamatsu N, et al. Pancreaticoduodenectomy after esophageal and gastric surgery preserving right gastroepiploic vessels. Arch Surg. 2006;141(2):205-208. doi:10.1001/archsurg.141.2.205
  10. Orii T, Yoshimura M, Kitahara H, Karasawa Y. Pylorus-preserving pancreatoduodenectomy for pancreatic head cancer after surgery for esophageal cancer with gastric tube reconstruction in a long-term survivor: A case report. Int J Surg Case Rep. 2019;55:92-98. doi:10.1016/j.ijscr.2019.01.024
  11. Okimoto S, Kobayashi T, Kuroda S, et al. Pancreaticoduodenectomy with preservation of gastric tube blood flow after esophagectomy: Report of a case. Int J Surg Case Rep. 2014;5(10):746-749. doi:10.1016/j.ijscr.2014.08.007
  12. Addeo P, Marzano E, Rosso E, Bachellier P, Jaeck D, Pessaux P. Gastroduodenal artery-preserving pancreaticoduodenectomy after subtotal esophagectomy and gastric pull-up. Langenbecks Arch Surg. 2011;396(5):693-697. doi:10.1007/s00423-011-0744-4
  13. Fragulidis GP, Athanasopoulos PG, Melemeni A, et al. Pylorus-preserving pancreaticoduodenectomy after transhiatal esophagectomy sparing the right gastroepiploic vessels and gastric tube. J Gastrointest Surg. 2011;15(2):367-370. doi:10.1007/s11605-010-1245-4
  14. Kurosaki I, Hatakeyama K, Nihei K, Suzuki T, Tsukada K. Thoracic esophagectomy combined with pylorus-preserving pancreatoduodenectomy in a one-stage procedure: report of a case. Surg Today. 2000;30(2):168-172. doi:10.1007/s005950050036
  15. Uehara H, Kondo S, Hirano S, Ambo Y, Tanaka E, Katoh H. Gastric tube-preserving pancreatoduodenectomy after esophagectomy and reconstruction using the gastric tube: report of a case. Surg Today. 2004;34(7):623-625. doi:10.1007/s00595-004-2767-8
  16. Hirashita T, Iwashita Y, Nakanuma H, et al. Pylorus-preserving pancreatoduodenectomy preserving the right gastroepiploic vessels following proximal gastrectomy: report of two cases. Surg Case Rep. 2019;5(1):41. Published 2019 Mar 12. doi:10.1186/s40792-019-0599-4
  17. Nagai H, Ohki J, Kondo Y, Yasuda T, Kasahara K, Kanazawa K. Pancreatoduodenectomy with preservation of the pylorus and gastroduodenal artery. Ann Surg. 1996;223(2):194-198. doi:10.1097/00000658-199602000-00012
  18. Inoue A, Akita H, Eguchi H, et al. Gastric conduit-preserving, radical pancreaticoduodenectomy with microvascular reconstruction for pancreatic head cancer after esophagectomy: report of a case. Surg Today. 2014;44(4):786-791. doi:10.1007/s00595-013-0791-2
  19. Okochi M, Ueda K, Sakaba T, Kenjo A, Gotoh M. Right gastro-omental artery reconstruction after pancreaticoduodenectomy for subtotal esophagectomy and gastric pull-up. Int J Surg Case Rep. 2015;15:42-45. doi:10.1016/j.ijscr.2015.08.020
  20. Minagawa M, Ichida H, Yoshioka R, et al. Pancreaticoduodenectomy with reconstructing blood flow of the gastric conduit after esophagectomy with concomitant celiac axis stenosis: a case report. Surg Case Rep. 2020;6(1):267. Published 2020 Oct 8. doi:10.1186/s40792-020-01019-0
  21. de Garcia de la Vega M, Faber B, Schalbar C, Foxius A, Groot-Koerkamp H, Decker G. Combined one-stage esophagectomy and duodeno-pancreatectomy for synchronous cancers of the esophagus and pancreatic ampulla in an elderly patient. Acta Chir Belg. 2021;121(1):46-50. doi:10.1080/00015458.2019.1631628
  22. Belyaev O, Muller CA, Uhl W. Satisfactory long-term results after simultaneous resection of the esophagus, stomach and pancreas. Langenbecks Arch Surg. 2009;394(2):383-385. doi:10.1007/s00423-008-0397-0
  23. Jayaprakash N, O’Kelly F, Lim KT, Reynolds JV. Management of synchronous adenocarcinoma of the esophago-gastric junction and ampulla of Vater: case report of a surgically challenging condition. Patient Saf Surg. 2009;3(1):23. Published 2009 Sep 28. doi:10.1186/1754-9493-3-23
  24. Honig SE, Lundgren MP, Kowalski TE, Lavu H, Yeo CJ. Advanced Endoscopic Rescue of a Complication (Duodenojejunostomy Leak) After a Pylorus-Preserving Pancreaticoduodenectomy in a Post-Esophagectomy Patient with Pancreatic Adenocarcinoma: A Case Report and Review of the Literature. J Pancreat Cancer. 2020;6(1):5-11. Published 2020 Feb 6. doi:10.1089/pancan.2019.0016
  25. Chiorean EG, Chiaro MD, Tempero MA, et al. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(7):753-782. doi:10.6004/jnccn.2023.0034